US EditionRwanda: 10 Things to Know About Effectiveness of New HIV Injectable Drug
SOUTH AFRICA, JUL 17 – Six-month injectable PrEP aims to improve adherence and reduce stigma among high-risk groups, with studies showing 89% of patients prefer long-acting regimens over daily pills, experts said.
7 Articles
7 Articles
Rwanda: 10 Things to Know About Effectiveness of New HIV Injectable Drug
Globally, an estimated 4,000 adolescent girls and young women become infected with HIV each week, with sub-Saharan Africa accounting for more than 60% of these new infections, according to the World Health Organization (WHO).
Kigali – For people living with HIV who have low treatment adherence, the long-acting injection of the HIV drug cabotegravir (CAB) is an effective alternative to daily oral antiretroviral therapy (ART). However, a 2- or 3-day interruption of ART is inferior to daily dosing and should not be...
HIV activists, scientists press for change, fueled by excitement for new PrEP tools
KIGALI, RWANDA — Emotions ran high this week at one of the world’s leading HIV science conferences after months of adapting in real-time to funding pullbacks that have shuttered or stalled critical HIV programs. The financial ...
10 things to know about effectiveness of new HIV injectable drug
Globally, an estimated 4,000 adolescent girls and young women become infected with HIV each week, with sub-Saharan Africa accounting for more than 60% of these new infections, according to the World Health Organization (WHO). In this region, young women are vulnerable due to a combination of structural inequalities, limited access to health services, and biological risk factors. ALSO READ: Rwanda in talks to get new HIV injectable drug While exi…
HIV: Preference for Bi-weekly Injection Treatment HIV: A Revolution in Treatment? The Volition study reveals a preference for injections to... The post HIV: Preference for Bi-weekly Injection Treatment appeared first on World News.
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
